SRC and hepatocellular carcinoma: The saracatinib-resistant HCC cell lines were then treated with oxaliplatin at increasing concentrations, yielding significantly enhanced resistance to oxaliplatin with increased IC50 in both MHCC97L-Src (108.71 ± 11.24 μmol/L vs. 20.85 ± 4.86 μmol/L; p = 0.0092; Fig. 3D, a) and Hep3B-Src (27.01 ± 4.59 μmol/L vs. 5.29 ± 1.29 μmol/L; p = 0.0106; Fig. 3D, b) compared to wild-type cells.